Alnylam Pharmaceuticals, Inc. (ALNY)
236.06
-0.16
(-0.07%)
USD |
NASDAQ |
Aug 24, 16:00
237.08
+1.02
(+0.43%)
After-Hours: 20:00
Alnylam Pharmaceuticals Net Income (Quarterly) : 164.49M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 164.49M |
| March 31, 2026 | 205.99M |
| December 31, 2025 | 186.42M |
| September 30, 2025 | 251.08M |
| June 30, 2025 | -72.23M |
| March 31, 2025 | -18.25M |
| December 31, 2024 | -83.76M |
| September 30, 2024 | -111.57M |
| June 30, 2024 | -16.89M |
| March 31, 2024 | -65.94M |
| December 31, 2023 | -137.87M |
| September 30, 2023 | 147.75M |
| June 30, 2023 | -276.02M |
| March 31, 2023 | -174.10M |
| December 31, 2022 | -207.49M |
| September 30, 2022 | -405.92M |
| June 30, 2022 | -277.40M |
| March 31, 2022 | -240.34M |
| December 31, 2021 | -258.46M |
| September 30, 2021 | -204.51M |
| June 30, 2021 | -189.56M |
| March 31, 2021 | -200.29M |
| December 31, 2020 | -243.54M |
| September 30, 2020 | -253.29M |
| June 30, 2020 | -179.23M |
| Date | Value |
|---|---|
| March 31, 2020 | -182.22M |
| December 31, 2019 | -276.18M |
| September 30, 2019 | -208.54M |
| June 30, 2019 | -219.48M |
| March 31, 2019 | -181.92M |
| December 31, 2018 | -211.44M |
| September 30, 2018 | -245.28M |
| June 30, 2018 | -163.56M |
| March 31, 2018 | -141.21M |
| December 31, 2017 | -142.23M |
| September 30, 2017 | -122.94M |
| June 30, 2017 | -118.42M |
| March 31, 2017 | -107.29M |
| December 31, 2016 | -112.93M |
| September 30, 2016 | -104.07M |
| June 30, 2016 | -90.13M |
| March 31, 2016 | -102.97M |
| December 31, 2015 | -90.72M |
| September 30, 2015 | -76.79M |
| June 30, 2015 | -71.78M |
| March 31, 2015 | -50.78M |
| December 31, 2014 | -21.39M |
| September 30, 2014 | -43.99M |
| June 30, 2014 | -44.07M |
| March 31, 2014 | -250.94M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -114.65M |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| Vertex Pharmaceuticals, Inc. | 1.100B |
| BridgeBio Pharma, Inc. | -155.89M |
| Pfizer Inc. | -246.00M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.291B |
| Total Expenses (Quarterly) | 1.126B |
| EPS Diluted (Quarterly) | 1.207 |
| Enterprise Value | 31.27B |
| Gross Profit Margin (Quarterly) | 76.88% |
| Profit Margin (Quarterly) | 12.74% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 3.08% |
| Normalized Earnings Yield | 2.438 |